CABLIVI's dosing regimen is initiated with plasma exchange, involving an intravenous loading dose followed by daily subcutaneous injections, which continue for a defined period post-plasma exchange, with provisions for extension or early discontinuation based on clinical response.

CABLIVI Dosing and Administration

The initial administration of CABLIVI on day one consists of an 11 mg intravenous bolus injection, administered at least 15 minutes prior to commencing plasma exchange (PEX). This is followed by an 11 mg subcutaneous injection after PEX completion on the same day. For subsequent days during the daily PEX period, a once-daily subcutaneous injection of 11 mg is administered following each PEX session. After the PEX period concludes, treatment continues with an 11 mg subcutaneous injection once daily for 30 days. If signs of persistent underlying disease, such as suppressed ADAMTS13 activity levels, remain, this daily subcutaneous treatment may be extended for a maximum of 28 additional days. However, CABLIVI should be discontinued if a patient experiences more than two recurrences of aTTP while on the medication. Instructions for missed doses vary depending on whether they occur during or after the plasma exchange period.